Clinuvel Pharmaceuticals Limited (CLVLF)
OTHER OTC:CLVLF
Earnings Data
Report Date
Sep 01, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.36Last Year’s EPS
0.31Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.Company Guidance
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Sustained Profitability
CLINUVEL reported its 20th consecutive profitable period since commercial operations began and maintained overall profitability despite expansionary spending (company noted only ~4% of biotechs deliver sustained profit).
Strong Cash Position and Balance Sheet
Cash reserves rose by $9 million to $233 million (highest in company history); net assets increased by $8.2 million to just under $250 million. The company remains debt-free for the 21st consecutive year and reports no equity dilution since March 2016.
Positive Operating Cash Flows and Yield on Cash
The business continued to generate strong positive net operating cash flows; interest income rose 14% to $5.3 million as cash was deployed into longer-term term deposits with an average yield around 4.5% and avg maturity ~300 days.
Commercial Execution — Europe and U.S. Expansion
European volumes grew notably after the EMA raised the maximum implants per year from 4 to 6 (Sep 2025), driving uptake. North America reached the target of ~120 sites, supporting continued patient demand. Reported revenue split ~53% U.S. / 47% rest of world for the period.
Strategic R&D and In-House Capability Build
Management intentionally increased in-house capabilities (clinical, data science, manufacturing/process) to retain control and reduce CRO dependence. Key program milestones/catalysts include top-line CUV105 vitiligo results expected H2 2026, start of CUV107, preclinical peptide formulation readouts later in the year, and planned expansion of the Singapore R&D center over the next five years.
Funded Development Pathway
Management reaffirmed sufficient cash runway to fund full vitiligo clinical program and near-term development activities; FY expense guidance reiterated at approx. $55–$58 million (ex-capex).
CLVLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLVLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $8.14 | $7.64 | -6.14% |
Aug 27, 2025 | $8.46 | $8.13 | -3.90% |
Feb 26, 2025 | $6.92 | $6.92 | 0.00% |
Aug 29, 2024 | $9.33 | $10.35 | +10.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Clinuvel Pharmaceuticals Limited (CLVLF) report earnings?
Clinuvel Pharmaceuticals Limited (CLVLF) is schdueled to report earning on Sep 01, 2026, TBA (Confirmed).
What is Clinuvel Pharmaceuticals Limited (CLVLF) earnings time?
Clinuvel Pharmaceuticals Limited (CLVLF) earnings time is at Sep 01, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLVLF EPS forecast?
CLVLF EPS forecast for the fiscal quarter 2026 (Q4) is 0.36.